127.97
-1.04 (-0.81%)
| Previous Close | 129.01 |
| Open | 128.72 |
| Volume | 69,197 |
| Avg. Volume (3M) | 236,119 |
| Market Cap | 3,149,584,896 |
| Price / Earnings (Forward) | 18.62 |
| Price / Sales | 1.32 |
| Price / Book | 1.49 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | -3.87% |
| Operating Margin (TTM) | 4.89% |
| Diluted EPS (TTM) | -3.83 |
| Quarterly Revenue Growth (YOY) | 6.70% |
| Total Debt/Equity (MRQ) | 80.57% |
| Current Ratio (MRQ) | 2.59 |
| Operating Cash Flow (TTM) | 209.57 M |
| Levered Free Cash Flow (TTM) | 77.29 M |
| Return on Assets (TTM) | 1.79% |
| Return on Equity (TTM) | -4.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | ICU Medical, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | 1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 3.04% |
| % Held by Institutions | 101.86% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 180.00 (Raymond James, 40.66%) | Buy |
| Median | 162.50 (26.98%) | |
| Low | 145.00 (Piper Sandler, 13.31%) | Buy |
| Average | 162.50 (26.98%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 116.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 15 Aug 2025 | 145.00 (13.31%) | Buy | 120.95 |
| Raymond James | 08 Aug 2025 | 180.00 (40.66%) | Buy | 112.85 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GREENBERG DAVID C. | 126.62 | - | 1,200 | 151,944 |
| Aggregate Net Quantity | 1,200 | |||
| Aggregate Net Value ($) | 151,944 | |||
| Aggregate Avg. Buy ($) | 126.62 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GREENBERG DAVID C. | Director | 27 Aug 2025 | Buy (+) | 1,200 | 126.62 | 151,944 |
| Date | Type | Details |
|---|---|---|
| 21 Aug 2025 | Announcement | ICU Medical to Participate in Upcoming Investor Conferences |
| 07 Aug 2025 | Announcement | ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance |
| 24 Jul 2025 | Announcement | ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |